ISIN

Inventiva reports 2021 first half financial results and provides a corporate update

ISIN, Psoriasis Area and Severity Index, MPS, G&A, Insurance, Computational chemistry, PASI, POSI, Review, Compliance, Factor X, Pharmacokinetics, Achievement, MPS VI, Degenerative disease, Conference, ADSS, Mission statement, Patient, Chronic liver disease, Independent, American depositary receipt, Adult, Nasdaq, Biology, Phase, NASH, Breakthrough therapy, Company, Program, Psoriasis, Lists of diseases, Pharmacology, IVA, ATM, Fast track (FDA), IPO, Cirrhosis, Research, R, Safety, CIR, Combined, AbbVie, Time, Pharmaceutical industry, Reinsurance, Cryptocurrency, Lithium, Ridesharing company, Bank, Audit, Medical device, Animal
Monday, September 20, 2021 - 9:10pm

Revenues for the first half of 2021 reached 0.1 million, stable compared to the first half of 2020.

Key Points: 
  • Revenues for the first half of 2021 reached 0.1 million, stable compared to the first half of 2020.
  • Net financial income amounted to 0.8 million in the first half of 2021, mainly linked to exchange rate variation.
  • Net cash used in operating activities amounted to 19.8 million and 7.2 million in the first half of 2021 and 2020, respectively.
  • The financial statements of the first half of 2021 were approved by Inventivas Board of Directors on September 16, 2021.

ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021

ISIN, Asparagine, Pancreatic cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Triple-negative breast cancer, Metabolism, Program, Growth, GMP, Food, IST, European Medicines Agency, Income, Webcast, Q&A, CEO, PAC, Medicine, ATM, Technology, Survival, Acute lymphoblastic leukemia, ALL, Cancer, FDA, Fast Track, 150, Company, CMO, Phase II, CAC All-Tradable, CAC Mid 60, Euronext, Patient, CAC, Marginal cost, Nasdaq, CET, Organic acid, Pharmaceutical industry, Video game console, Property management, Animal
Monday, September 20, 2021 - 9:05pm

The 0.6 million increase in financial result was mostly related to foreign currency gains on U.S. dollar.

Key Points: 
  • The 0.6 million increase in financial result was mostly related to foreign currency gains on U.S. dollar.
  • As of June 30, 2021, ERYTECH had cash and cash equivalents totaling 46.3 million (approximately $54.9 million), compared with 44.4 million on December 31, 2020 and 37.4 million on March 31, 2021.
  • The Company believes that its current cash position can fund its planned operating expenses and current programs into the second quarter of 2022.
  • ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

ENERGISME: Sandrine Cauvin joins Energisme as Administrative and Financial Director.

Kepler, Software as a service, ISIN, SME, Administration, ODDO BHF, Regulatory News Service, CIIA, Chief, Metal, Business, Finance minister, Marketing, Industry, Company, Communication, Growth, SFAF, European Institute, Research, Certified International Investment Analyst, Acceleration, Euronext Growth, Security (finance), Financial services, Management
Monday, September 20, 2021 - 5:06pm

ENERGISME: Sandrine Cauvin joins Energisme as Administrative and Financial Director.

Key Points: 
  • ENERGISME: Sandrine Cauvin joins Energisme as Administrative and Financial Director.
  • Sandrine Cauvin said: "I am proud to join the Energisme team.
  • ENERGISME (ISIN code: FR0013399359/Ticker: ALNRG) has been listed on the Euronext Growth market since July 2020.
  • ENERGISME is eligible for SME personal equity plans and qualifies as a BPI Innovative Company and BPI Excellence.

Sistema PJSFC: Sistema reports acquisition of shares under buyback programme

ISIN, Company, MOEX, LSE, SSA, Security (finance)
Monday, September 20, 2021 - 5:06pm

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • Moscow, September 20 2021 - Sistema PJSFC ("Sistema" or the "Company") (LSE: SSA, MOEX: AFKS), a publicly traded Russian investment company, announces that its wholly-owned subsidiary Sistema Finance JSC ("Sistema Finance") acquired 6810600 of the Company's ordinary shares (ISIN: RU000A0DQZE3) under the Company's buyback programme that will be carried out till 17 September 2022 (the "Programme").
  • The shares were purchased on Moscow Exchange (MOEX) by the broker on behalf of Sistema Finance and transferred to Sistema Finance.

Buybacks of shares in Alfa Laval during week 37 2021

ISIN, Board of directors, SEK, LEI, Share repurchase, Alfa Laval, MAR, Director, Online gambling
Monday, September 20, 2021 - 4:34pm

LUND, Sweden, Sept. 20, 2021 /PRNewswire/ -- During the period September 13 - September 17, 2021, Alfa Laval AB (publ) ("Alfa Laval") (LEI code: 549300UCKT2UK88AG251) has repurchased in total 126,900 own shares (ISIN: SE0000695876) as part of the share buyback program initiated by the Board of Directors in order to secure optimized capital structure.

Key Points: 
  • LUND, Sweden, Sept. 20, 2021 /PRNewswire/ -- During the period September 13 - September 17, 2021, Alfa Laval AB (publ) ("Alfa Laval") (LEI code: 549300UCKT2UK88AG251) has repurchased in total 126,900 own shares (ISIN: SE0000695876) as part of the share buyback program initiated by the Board of Directors in order to secure optimized capital structure.
  • The share buybacks form part of the SEK 2 billion share buyback program, which Alfa Laval announced on April 27, 2021.
  • The share buyback program, which runs between April 28, 2021 and April 25, 2022, is being carried out in accordance with the EU Market Abuse Regulation (MAR) and the Commission Delegated Regulation 2016/1052 (the so-called Safe Harbour Regulation).
  • Shares in Alfa Laval have been repurchased as follows:

DGAP-News: M1 Kliniken AG continues growth course

ISIN, EUR, News, DGAP, Wolfsburg, Aachen, Bed, Security (finance)
Monday, September 20, 2021 - 3:17pm

Expected annual sales of over EUR 50 million in the Beauty segment in 2021

Key Points: 
  • Expected annual sales of over EUR 50 million in the Beauty segment in 2021
    Berlin, 20.09.2021 - M1 Kliniken AG (ISIN: DE000A0STSQ8) sustainably continues its growth course in the third quarter of 2021.
  • For September 2021, M1 Kliniken AG has set course for a new record month.
  • M1 Kliniken AG is the leading provider of beauty medical health services in Germany.
  • With its investment in HAEMATO AG, M1 Kliniken AG is also in a position to exploit the sales and earnings potential of its treatment products in the medical aesthetic field.

Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

ISIN, Ketamine, Nature, Person, CUSIP, DELC, Growth, Pain, Insurance, Transaction, Mergers and acquisitions, Industry, News, Failure, Compliance, Health, Multimedia, Member, IP, Private Securities Litigation Reform Act, CEO, VWAP, Awareness, Science, Conditional sentence, Tripura Merger Agreement, Partnership, Reality Sandwiches, USD, Regulation, KIC, The Exchange, FDA, Hospital, Acquisition, Company, Health Canada, R, Footprint, Time, Education, Canadian Securities Exchange, CSE, Patient, MDMA, Phrase, KWC, FRA, Legislation, COVID-19, Research, Psilocybin, Pain disorder, Pharmaceutical industry, Security (finance), Risk management
Monday, September 20, 2021 - 1:30pm

The Transaction (defined below) establishes Delic as the largest psychedelic organization operating in the United States.

Key Points: 
  • The Transaction (defined below) establishes Delic as the largest psychedelic organization operating in the United States.
  • Joining Ketamine Infusion Centers LLC ("KIC") (acquired June, 2021), which has grown steadily with revenues in excess of USD$4.2MM since 2019.
  • Established history of providing ketamine infusion services: The management team at KWC has been in business for 6 years expanding services throughout the United States.
  • Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

ISIN, SOC, Docetaxel, Oncology, Failure, Standard of care, Poi, CT, Gustave Roussy, Patient, European Society for Medical Oncology, Population, NSCLC, Principal, Large-cell lung carcinoma, ECOG, DCR, Survival, ESMO, Clinical research, IO, Pemetrexed, PFS, GLOBE, Pharmaceutical industry, Silviculture
Monday, September 20, 2021 - 12:45pm

Applying the 2020 SITC(2) guidelines defining resistance categories for PD-1/PD-L1 checkpoint inhibitors to our trial, developed while this trial was ongoing, suggest there is great potential for Tedopi in patients with secondary resistance(3).

Key Points: 
  • Applying the 2020 SITC(2) guidelines defining resistance categories for PD-1/PD-L1 checkpoint inhibitors to our trial, developed while this trial was ongoing, suggest there is great potential for Tedopi in patients with secondary resistance(3).
  • Therefore, we are very pleased to share such very promising results demonstrating the substantial benefits of Tedopi for NSCLC patients with secondary resistance to anti-PD-1 treatments, a hard to treat patient population with high medical need.
  • The Tedopi treatment was compared to docetaxel or pemetrexed chemotherapy (CT) treatments in this patient population, with overall survival as the primary endpoint of the trial.
  • A good tolerance profile of Tedopi with fewer Severe Adverse Events (Tedopi 38% vs SoC 68%, p

Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

ISIN, Ketamine, Nature, Person, CUSIP, DELC, Growth, Pain, Insurance, Transaction, Mergers and acquisitions, Industry, News, Failure, Compliance, Health, Multimedia, Member, IP, Private Securities Litigation Reform Act, CEO, VWAP, Awareness, Science, Conditional sentence, Tripura Merger Agreement, Partnership, Reality Sandwiches, USD, Regulation, KIC, The Exchange, FDA, Hospital, Acquisition, Company, Health Canada, R, Footprint, Time, Education, Canadian Securities Exchange, CSE, Patient, MDMA, Phrase, KWC, FRA, Legislation, COVID-19, Research, Psilocybin, Pain disorder, Pharmaceutical industry, Security (finance), Risk management
Monday, September 20, 2021 - 12:20pm

The Transaction (defined below) establishes Delic as the largest psychedelic organization operating in the United States.

Key Points: 
  • The Transaction (defined below) establishes Delic as the largest psychedelic organization operating in the United States.
  • Joining Ketamine Infusion Centers LLC ("KIC") (acquired June, 2021), which has grown steadily with revenues in excess of USD$4.2MM since 2019.
  • Established history of providing ketamine infusion services: The management team at KWC has been in business for 6 years expanding services throughout the United States.
  • Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation.

DGAP-News: TTL Beteiligungs- und Grundbesitz-AG: TTL - Subscription period for capital increase starts today

ISIN, Exercise, TTO, Sale, DIC, CEO, Growth, Capital, Investment, Authorised capital, TTL, Euro, Security (finance), Real estate
Monday, September 20, 2021 - 8:00am

Cash capital increase from Authorised Capital with subscription rights:

Key Points: 
  • Cash capital increase from Authorised Capital with subscription rights:
    TTL Beteiligungs- und Grundbesitz-AG ("TTL", "TTL AG") (ISIN DE0007501009) starts today with the subscription period for its capital increase with subscription rights announced on 15 September 2021 by ad hoc release.
  • Existing shareholders may subscribe for New Shares at the subscription price of 2.25 Euro per share by exercising their subscription rights at a subscription ratio of 6:1.
  • "The company has made the decision to carry out a capital increase with subscription rights enabling TTL shareholders to participate in TTL's further growth," explains Reichert additionally.
  • The subscription rights from the capital increase are generally transferable, but there is no trading in subscription rights on the stock exchange.